In 2018, lenvatinib, a multikinase inhibitor with a spectrum of activity against VEGFR, FGF receptor (FGFR), PDGFR, rearranged during transfection (RET), and stem cell factor receptor (KIT), was approved by the US FDA and China's NMPA as a frontline therapeutic option for patients afflicted with unresectable HCC [526]. This evidence concerns the gene KDR and hepatocellular carcinoma.